DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $561,496,186 | +30.1% | 2,263,291 | +25.8% | 0.51% | +32.6% |
| Q2 2023 | $431,676,841 | -26.1% | 1,798,945 | -22.4% | 0.39% | -28.8% |
| Q1 2023 | $584,399,660 | -7.1% | 2,318,886 | -2.1% | 0.54% | -12.0% |
| Q4 2022 | $628,769,581 | +0.6% | 2,368,801 | -2.0% | 0.62% | -5.5% |
| Q3 2022 | $624,812,000 | +42.5% | 2,418,049 | +39.9% | 0.65% | +47.8% |
| Q2 2022 | $438,320,000 | -11.7% | 1,728,705 | +2.2% | 0.44% | +4.8% |
| Q1 2022 | $496,465,000 | -15.1% | 1,692,164 | -6.0% | 0.42% | -8.3% |
| Q4 2021 | $584,794,000 | +28.6% | 1,800,782 | +18.8% | 0.46% | +15.6% |
| Q3 2021 | $454,643,000 | +11.6% | 1,515,838 | -1.5% | 0.40% | +11.5% |
| Q2 2021 | $407,515,000 | +23.9% | 1,538,988 | +5.2% | 0.36% | +13.4% |
| Q1 2021 | $328,882,000 | +1.2% | 1,463,168 | -0.1% | 0.31% | -6.8% |
| Q4 2020 | $325,062,000 | -4.5% | 1,464,531 | -7.4% | 0.34% | -16.6% |
| Q3 2020 | $340,390,000 | +4.9% | 1,582,396 | -13.9% | 0.40% | +0.2% |
| Q2 2020 | $324,619,000 | +27.6% | 1,837,346 | -0.1% | 0.40% | +3.9% |
| Q1 2020 | $254,483,000 | -15.8% | 1,838,467 | -6.7% | 0.39% | +9.9% |
| Q4 2019 | $302,344,000 | -2.1% | 1,970,057 | -7.9% | 0.35% | -6.4% |
| Q3 2019 | $308,828,000 | -11.1% | 2,139,218 | -12.0% | 0.38% | -9.4% |
| Q2 2019 | $347,448,000 | -2.6% | 2,431,454 | -10.0% | 0.42% | -4.8% |
| Q1 2019 | $356,682,000 | +4.3% | 2,702,876 | -18.5% | 0.44% | -8.4% |
| Q4 2018 | $342,061,000 | -3.6% | 3,318,135 | +1.6% | 0.48% | +18.7% |
| Q3 2018 | $354,872,000 | +10.4% | 3,266,260 | +0.0% | 0.40% | +13.2% |
| Q2 2018 | $321,530,000 | +0.8% | 3,264,994 | -0.1% | 0.36% | -2.5% |
| Q1 2018 | $318,870,000 | +2.2% | 3,266,644 | -3.0% | 0.36% | +1.4% |
| Q4 2017 | $311,953,000 | +13.9% | 3,366,707 | +5.5% | 0.36% | +4.7% |
| Q3 2017 | $273,798,000 | +2.9% | 3,191,861 | +1.2% | 0.34% | +0.3% |
| Q2 2017 | $266,047,000 | -4.7% | 3,152,585 | -3.4% | 0.34% | -5.0% |
| Q1 2017 | $279,045,000 | +9.3% | 3,262,538 | -0.6% | 0.36% | +5.0% |
| Q4 2016 | $255,406,000 | -8.0% | 3,281,164 | -7.3% | 0.34% | -9.0% |
| Q3 2016 | $277,569,000 | -31.3% | 3,540,877 | -11.4% | 0.38% | -32.2% |
| Q2 2016 | $403,823,000 | +4.3% | 3,998,248 | -2.0% | 0.56% | +4.5% |
| Q1 2016 | $387,062,000 | -11.8% | 4,080,356 | -13.7% | 0.53% | -7.5% |
| Q4 2015 | $438,910,000 | +7.4% | 4,725,550 | -1.5% | 0.58% | +9.1% |
| Q3 2015 | $408,746,000 | -13.7% | 4,796,927 | -13.3% | 0.53% | +0.2% |
| Q2 2015 | $473,515,000 | -2.2% | 5,532,357 | -3.0% | 0.53% | +1.7% |
| Q1 2015 | $484,186,000 | -6.2% | 5,703,017 | -5.3% | 0.52% | -3.5% |
| Q4 2014 | $515,944,000 | +11.1% | 6,019,655 | -1.5% | 0.54% | +12.6% |
| Q3 2014 | $464,247,000 | -9.5% | 6,110,120 | -6.2% | 0.48% | -5.0% |
| Q2 2014 | $513,097,000 | +5.4% | 6,517,178 | +0.4% | 0.50% | +1.2% |
| Q1 2014 | $486,934,000 | -8.5% | 6,492,457 | -5.9% | 0.50% | -9.5% |
| Q4 2013 | $532,447,000 | -44.2% | 6,896,988 | -55.1% | 0.55% | -4.2% |
| Q3 2013 | $954,377,000 | +98.4% | 15,351,219 | +102.1% | 0.57% | -0.2% |
| Q2 2013 | $480,931,000 | – | 7,597,653 | – | 0.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |